Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma.

Katagiri S, Makishima H, Azuma K, Nannya Y, Saitoh Y, Yoshizawa S, Akahane D, Fujimoto H, Ito Y, Velaga R, Umezu T, Ohyashiki JH, Ogawa S, Ohyashiki K.

Haematologica. 2019 Nov 7. pii: haematol.2019.229856. doi: 10.3324/haematol.2019.229856. [Epub ahead of print]

2.

Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion.

Umezu T, Imanishi S, Yoshizawa S, Kawana C, Ohyashiki JH, Ohyashiki K.

Blood Adv. 2019 Nov 12;3(21):3228-3240. doi: 10.1182/bloodadvances.2019000403.

3.

Hyperactive behavioral phenotypes and an altered brain monoaminergic state in male offspring mice with perinatal hypothyroidism.

Umezu T, Kita T, Morita M.

Toxicol Rep. 2019 Oct 7;6:1031-1039. doi: 10.1016/j.toxrep.2019.10.005. eCollection 2019.

4.

Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review.

Takahashi M, Ozaki Y, Kizawa R, Masuda J, Sakamaki K, Kinowaki K, Umezu T, Kondoh C, Tanabe Y, Tamura N, Miura Y, Shigekawa T, Kawabata H, Baba N, Iguchi H, Takano T.

BMC Cancer. 2019 Oct 22;19(1):980. doi: 10.1186/s12885-019-6236-6.

5.

Author Correction: Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm.

Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, Asou N, Maeda T, Nakagata N, Iwama A, Ohyashiki K, Osato M, Sashida G.

Nat Commun. 2019 Aug 28;10(1):3943. doi: 10.1038/s41467-019-11919-x.

6.

A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome.

Asano M, Ohyashiki JH, Kobayashi-Kawana C, Umezu T, Imanishi S, Azuma K, Akahane D, Fujimoto H, Ito Y, Ohyashiki K.

Drug Des Devel Ther. 2019 May 30;13:1821-1833. doi: 10.2147/DDDT.S195071. eCollection 2019.

7.

Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm.

Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, Asou N, Maeda T, Nakagata N, Iwama A, Ohyashiki K, Osato M, Sashida G.

Nat Commun. 2019 Apr 10;10(1):1653. doi: 10.1038/s41467-019-09710-z. Erratum in: Nat Commun. 2019 Aug 28;10(1):3943.

8.

Maintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Katagiri S, Umezu T, Azuma K, Kobayashi C, Akahane D, Suguro T, Furuya N, Fujimoto H, Nakamura N, Ohyashiki JH, Ohyashiki K.

Bone Marrow Transplant. 2019 Jul;54(7):1148-1150. doi: 10.1038/s41409-019-0436-1. Epub 2019 Jan 22. No abstract available.

PMID:
30670826
9.

BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma.

Ito Y, Umezu T, Tadokoro K, Saito Y, Katagiri S, Suguro T, Asano M, Yoshizawa S, Akahane D, Tanaka Y, Fujimoto H, Okabe S, Gotoh M, Tauchi T, Kawana C, Ohyashiki JH, Nakamura N, Ohyashiki K.

Leuk Lymphoma. 2019 May;60(5):1283-1288. doi: 10.1080/10428194.2018.1529310. Epub 2018 Nov 27.

PMID:
30480474
10.

Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells.

Imanishi S, Umezu T, Kobayashi C, Ohta T, Ohyashiki K, Ohyashiki JH.

Front Pharmacol. 2018 Oct 16;9:1166. doi: 10.3389/fphar.2018.01166. eCollection 2018.

11.

Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell Transplantation.

Yoshizawa S, Umezu T, Saitoh Y, Gotoh M, Akahane D, Kobayashi C, Ohyashiki JH, Ohyashiki K.

Int J Mol Sci. 2018 Aug 23;19(9). pii: E2493. doi: 10.3390/ijms19092493.

12.

Stratification of mouse vaginal epithelium. 1. Development of three-dimensional models in vitro with clonal cell lines.

Ogawa-Tominaga M, Umezu T, Nakajima T, Tomooka Y.

Biol Reprod. 2018 Oct 1;99(4):718-726. doi: 10.1093/biolre/ioy114.

PMID:
29767686
13.

Stratification of mouse vaginal epithelium 2. Identification of factors inducing stratification.

Takashina R, Nakajima T, Umezu T, Komatsu K, Banba T, Asada T, Ohse K, Murakami Y, Tomooka Y.

Biol Reprod. 2018 Oct 1;99(4):727-734. doi: 10.1093/biolre/ioy113.

PMID:
29762632
14.

Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.

Umezu T, Imanishi S, Azuma K, Kobayashi C, Yoshizawa S, Ohyashiki K, Ohyashiki JH.

Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.

15.

Surgical Correction of Severe Kyphoscoliosis Associated with Crouzon Syndrome with Serious Postoperative Respiratory Problems: A Case Report.

Umezu T, Fujita N, Yagi M, Tsuji O, Nagoshi N, Ishii K, Nakamura M, Matsumoto M, Watanabe K.

JBJS Case Connect. 2017 Oct-Dec;7(4):e98. doi: 10.2106/JBJS.CC.17.00011.

PMID:
29280899
16.

Extracellular vesicle-mediated cell-cell communication in haematological neoplasms.

Ohyashiki JH, Umezu T, Ohyashiki K.

Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737). pii: 20160484. doi: 10.1098/rstb.2016.0484. Review.

17.

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells.

Imanishi S, Takahashi R, Katagiri S, Kobayashi C, Umezu T, Ohyashiki K, Ohyashiki JH.

Oncotarget. 2017 Jul 22;8(41):69906-69915. doi: 10.18632/oncotarget.19436. eCollection 2017 Sep 19.

18.

Hidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia.

Katagiri S, Umezu T, Azuma K, Asano M, Akahane D, Makishima H, Yoshida K, Watatani Y, Chiba K, Miyano S, Ogawa S, Ohyashiki JH, Ohyashiki K.

Leuk Lymphoma. 2018 Jun;59(6):1490-1493. doi: 10.1080/10428194.2017.1382696. Epub 2017 Oct 3. No abstract available.

PMID:
28972800
19.

Genetic variations of bone marrow mesenchymal stromal cells derived from acute leukemia and myelodysplastic syndrome by targeted deep sequencing.

Azuma K, Umezu T, Imanishi S, Asano M, Yoshizawa S, Katagiri S, Ohyashiki K, Ohyashiki JH.

Leuk Res. 2017 Nov;62:23-28. doi: 10.1016/j.leukres.2017.09.008. Epub 2017 Sep 21.

PMID:
28964959
20.

Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors.

Asano M, Umezu T, Katagiri S, Kobayashi C, Tauchi T, Gotoh M, Ando K, Okabe S, Ohyashiki JH, Ohyashiki K.

Int J Hematol. 2017 Apr;105(4):419-422. doi: 10.1007/s12185-017-2199-z. Epub 2017 Feb 14.

PMID:
28197964
21.

Guillain-Barré and Miller Fisher syndromes in patients with anti-hepatitis E virus antibody: a hospital-based survey in Japan.

Fukae J, Tsugawa J, Ouma S, Umezu T, Kusunoki S, Tsuboi Y.

Neurol Sci. 2016 Nov;37(11):1849-1851. Epub 2016 Jul 7.

PMID:
27389141
22.

Brain regions and monoaminergic neurotransmitters that are involved in mouse ambulatory activity promoted by bupropion.

Umezu T, Shibata Y.

Toxicol Rep. 2016 Jun 21;3:552-562. doi: 10.1016/j.toxrep.2016.06.005. eCollection 2016.

23.

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.

Ohyashiki K, Umezu T, Katagiri S, Kobayashi C, Azuma K, Tauchi T, Okabe S, Fukuoka Y, Ohyashiki JH.

Int J Mol Sci. 2016 Apr 15;17(4):570. doi: 10.3390/ijms17040570.

24.

Exosomes promote bone marrow angiogenesis in hematologic neoplasia: the role of hypoxia.

Ohyashiki JH, Umezu T, Ohyashiki K.

Curr Opin Hematol. 2016 May;23(3):268-73. doi: 10.1097/MOH.0000000000000235. Review.

PMID:
26866730
25.

[Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib].

Katagiri S, Tauchi T, Umezu T, Saito Y, Suguro T, Asano M, Yoshizawa S, Kitahara T, Akahane D, Tanaka Y, Fujimoto H, Okabe S, Gotoh M, Ito Y, Ohyashiki JH, Ohyashiki K.

Rinsho Ketsueki. 2015 Feb;56(2):216-9. doi: 10.11406/rinketsu.56.216. Japanese.

PMID:
25765803
26.

Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.

Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH.

Blood. 2014 Dec 11;124(25):3748-57. doi: 10.1182/blood-2014-05-576116. Epub 2014 Oct 15.

27.

Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?

Kajiyama H, Mizuno M, Shibata K, Umezu T, Suzuki S, Yamamoto E, Mitsui H, Sekiya R, Niimi K, Kawai M, Nagasaka T, Kikkawa F.

Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:305-10. doi: 10.1016/j.ejogrb.2014.07.046. Epub 2014 Aug 20.

PMID:
25203309
28.

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.

Ohyashiki JH, Ohtsuki K, Mizoguchi I, Yoshimoto T, Katagiri S, Umezu T, Ohyashiki K.

Drug Des Devel Ther. 2014 Aug 25;8:1151-9. doi: 10.2147/DDDT.S66812. eCollection 2014.

29.

Different behavioral effect dose-response profiles in mice exposed to two-carbon chlorinated hydrocarbons: influence of structural and physical properties.

Umezu T, Shibata Y.

Toxicol Appl Pharmacol. 2014 Sep 1;279(2):103-12. doi: 10.1016/j.taap.2014.05.012. Epub 2014 Jun 6.

PMID:
24910396
30.

Opioid needs of terminally ill patients with gynecologic malignancies.

Utsumi F, Kajiyama H, Sakata J, Higashi M, Niimi K, Sekiya R, Mitsui H, Suzuki S, Umezu T, Mizuno M, Yamamoto E, Shibata K, Kikkawa F.

Int J Clin Oncol. 2015 Apr;20(2):405-10. doi: 10.1007/s10147-014-0708-0. Epub 2014 Jun 7.

PMID:
24906849
31.

Possible association between stem-like hallmark and radioresistance in human cervical carcinoma cells.

Kumazawa S, Kajiyama H, Umezu T, Mizuno M, Suzuki S, Yamamoto E, Mitsui H, Sekiya R, Shibata K, Kikkawa F.

J Obstet Gynaecol Res. 2014 May;40(5):1389-98. doi: 10.1111/jog.12357. Epub 2014 Apr 21.

PMID:
24750491
32.

Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines.

Imanishi S, Umezu T, Ohtsuki K, Kobayashi C, Ohyashiki K, Ohyashiki JH.

Biochem Pharmacol. 2014 Jun 1;89(3):361-9. doi: 10.1016/j.bcp.2014.03.008. Epub 2014 Mar 26.

PMID:
24680865
33.

Is there any association between where patients spend the end of life and survival after anticancer treatment for gynecologic malignancy?

Kajiyama H, Utsumi F, Higashi M, Sakata J, Sekiya R, Mizuno M, Umezu T, Suzuki S, Yamamoto E, Mitsui H, Niimi K, Shibata K, Kikkawa F.

J Palliat Med. 2014 Mar;17(3):325-30. doi: 10.1089/jpm.2013.0366.

PMID:
24617316
34.

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology.

Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Sekiya R, Niimi K, Mitsui H, Yamamoto E, Kawai M, Nagasaka T, Kikkawa F.

J Gynecol Oncol. 2014 Jan;25(1):43-50. doi: 10.3802/jgo.2014.25.1.43. Epub 2014 Jan 8.

35.

A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age.

Kajiyama H, Mizuno M, Shibata K, Umezu T, Suzuki S, Yamamoto E, Mitsui H, Sekiya R, Niimi K, Kawai M, Nagasaka T, Kikkawa F.

Int J Clin Oncol. 2014 Oct;19(5):921-7. doi: 10.1007/s10147-013-0645-3. Epub 2013 Dec 5.

PMID:
24306200
36.

Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells.

Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH.

J Biol Chem. 2013 Nov 29;288(48):34343-51. doi: 10.1074/jbc.M113.480822. Epub 2013 Oct 16.

37.

A patient who experienced thyroid storm complicated by rhabdomyolysis, deep vein thrombosis, and a silent pulmonary embolism: a case report.

Umezu T, Ashitani K, Toda T, Yanagawa T.

BMC Res Notes. 2013 May 20;6:198. doi: 10.1186/1756-0500-6-198.

38.

Structure of perosamine-containing polysaccharide, a component of the sheath of Thiothrix fructosivorans.

Kondo K, Umezu T, Shimura S, Narizuka R, Koizumi J, Mashima T, Katahira M, Takeda M.

Int J Biol Macromol. 2013 Aug;59:59-66. doi: 10.1016/j.ijbiomac.2013.04.013. Epub 2013 Apr 12.

PMID:
23587998
39.

The expression and characterization of endoglin in uterine leiomyosarcoma.

Mitsui H, Shibata K, Mano Y, Suzuki S, Umezu T, Mizuno M, Yamamoto E, Kajiyama H, Kotani T, Senga T, Kikkawa F.

Clin Exp Metastasis. 2013 Aug;30(6):731-40. doi: 10.1007/s10585-013-9574-9. Epub 2013 Feb 9.

PMID:
23397382
40.

Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease.

Soeda S, Ohyashiki JH, Ohtsuki K, Umezu T, Setoguchi Y, Ohyashiki K.

Int J Mol Med. 2013 Mar;31(3):533-9. doi: 10.3892/ijmm.2013.1251. Epub 2013 Jan 21.

PMID:
23338559
41.

Contrast-enhanced ultrasonography using Sonazoid(®) is useful for diagnosis of malignant ovarian tumors: comparison with Doppler ultrasound.

Kumazawa S, Umezu T, Kanayama Y, Kamiyama N, Suzuki S, Mizuno M, Kajiyama H, Shibata K, Kikkawa F.

J Med Ultrason (2001). 2013 Jan;40(1):81-4. doi: 10.1007/s10396-012-0380-9. Epub 2012 Jul 4.

PMID:
27276932
42.

A spatial relationship between sheath elongation and cell proliferation in Sphaerotilus natans.

Takeda M, Umezu T, Kawasaki Y, Shimura S, Kondo K, Koizumi J.

Biosci Biotechnol Biochem. 2012;76(12):2357-9. Epub 2012 Dec 7.

43.

High expression of N-acetylglucosaminyltransferase IVa promotes invasion of choriocarcinoma.

Niimi K, Yamamoto E, Fujiwara S, Shinjo K, Kotani T, Umezu T, Kajiyama H, Shibata K, Ino K, Kikkawa F.

Br J Cancer. 2012 Dec 4;107(12):1969-77. doi: 10.1038/bjc.2012.496. Epub 2012 Nov 20.

44.

The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.

Katagiri S, Umezu T, Ohyashiki JH, Ohyashiki K.

Br J Haematol. 2013 Jan;160(2):269-71. doi: 10.1111/bjh.12111. Epub 2012 Nov 1. No abstract available.

PMID:
23116058
45.

Expression of Twist enhances risk of poor oncologic outcome in patients with stage Ib to II cervical carcinoma with lymphovascular space involvement.

Kajiyama H, Shibata K, Umezu T, Mizuno M, Suzuki S, Yamamoto E, Fujiwara S, Kikkawa F.

Hum Pathol. 2013 Feb;44(2):181-8. doi: 10.1016/j.humpath.2012.05.015. Epub 2012 Sep 10.

PMID:
22974479
46.

Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders.

Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, Iida S, Ohyashiki K.

Blood Cancer J. 2012 Jan;2(1):e53. doi: 10.1038/bcj.2011.51. Epub 2012 Jan 20.

47.

Leukemia cell to endothelial cell communication via exosomal miRNAs.

Umezu T, Ohyashiki K, Kuroda M, Ohyashiki JH.

Oncogene. 2013 May 30;32(22):2747-55. doi: 10.1038/onc.2012.295. Epub 2012 Jul 16.

PMID:
22797057
48.

Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma.

Kajiyama H, Shibata K, Mizuno M, Yamamoto E, Fujiwara S, Umezu T, Suzuki S, Nakanishi T, Nagasaka T, Kikkawa F.

Int J Gynecol Cancer. 2012 Jun;22(5):801-6. doi: 10.1097/IGC.0b013e3182540145.

PMID:
22617480
49.

Is there any association between retroperitoneal lymphadenectomy and survival benefit in advanced stage epithelial ovarian carcinoma patients?

Sakai K, Kajiyama H, Umezu T, Shibata K, Mizuno M, Suzuki S, Kawai M, Nagasaka T, Kikkawa F.

J Obstet Gynaecol Res. 2012 Jul;38(7):1018-23. doi: 10.1111/j.1447-0756.2011.01826.x. Epub 2012 May 8.

PMID:
22568659
50.

Unusual effects of nicotine as a psychostimulant on ambulatory activity in mice.

Umezu T.

ISRN Pharmacol. 2012;2012:170981. doi: 10.5402/2012/170981. Epub 2012 Mar 20.

Supplemental Content

Support Center